|
"shan ys"的相關文件
顯示項目 121-130 / 133 (共14頁)
<< < 5 6 7 8 9 10 11 12 13 14 > >>
每頁顯示[10|25|50]項目
| 國家衛生研究院 |
2015-06 |
Comprehensive analysis of the incidence and survival patterns of lung cancer by histologies, including rare subtypes, in the era of molecular medicine and targeted therapy: A nation-wide cancer registry-based study from Taiwan
|
Chang, JS;Chen, LT;Shan, YS;Lin, SF;Hsiao, SY;Tsai, CR;Yu, SJ;Tsai, HJ |
| 國家衛生研究院 |
2015-05 |
A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer
|
Chen, JS;Hsu, C;Chiang, NJ;Tsai, CS;Tsou, HH;Huang, SF;Bai, LY;Chang, IC;Shiah, HS;Ho, CL;Yen, CJ;Lee, KD;Chiu, CF;Rau, KM;Yu, MS;Yang, Y;Hsieh, RK;Chang, JY;Shan, YS;Chao, Y;Chen, LT |
| 國家衛生研究院 |
2015-05 |
A phase II study of sequential capecitabine plus oxaliplatin (XELOX) followed by docetaxel plus capecitabine (TX) in patients with unresectable gastric adenocarcinoma: The TCOG T3211 trial
|
Chen, MH;Lin, JS;Hsiao, CF;Shan, YS;Chen, YC;Chen, LT;Liu, TW;Li, CP;Chao, Y |
| 國家衛生研究院 |
2015-01 |
Expanded analyses of napoli-1: Phase 3 study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
|
Chen, LT;Von Hoff, DD;Li, CP;Wang-Gillam, A;Bodoky, G;Dean, AP;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Hubner, R;Chiu, CF;Schwartsmann, G;Siveke, JT;Braiteh, FS;Moyo, VM;Belanger, B;Bayever, E |
| 國家衛生研究院 |
2014-01 |
Impact of ROS1, ALK, and/or MET expression level on the therapeutic efficacy of GEMOX with and without cetuximab in ABTC: A post hoc analysis of a randomized phase II trial
|
Chiang, NJ;Hsu, C;Chen, JS;Tsou, HH;Chao, Y;Shan, YS;Huang, SF;Chiu, CF;Lee, KD;Chen, LT |
| 國家衛生研究院 |
2013-11 |
A gene expression signature of epithelial tubulogenesis and a role for ASPM in pancreatic tumor progression
|
Wang, WY;Hsu, CC;Wang, TY;Li, CR;Hou, YC;Chu, JM;Lee, CT;Liu, MS;Su, JJ;Jian, KY;Huang, SS;Jiang, SS;Shan, YS;Lin, PW;Shen, YY;Lee, MT;Chan, TS;Chang, CC;Chen, CH;Chang, IS;Lee, YL;Chen, LT;Tsai, KK |
| 國家衛生研究院 |
2013-11 |
Management of gastric cancer in Asia: Resource-stratified guidelines
|
Shen, L;Shan, YS;Hu, HM;Price, TJ;Sirohi, B;Yeh, KH;Yang, YH;Sano, T;Yang, HK;Zhang, X;Park, SR;Fujii, M;Kang, YK;Chen, LT |
| 國家衛生研究院 |
2013-08 |
A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer
|
Ko, AH;Tempero, MA;Shan, YS;Su, WC;Lin, YL;Dito, E;Ong, A;Wang, YW;Yeh, CG;Chen, LT |
| 國家衛生研究院 |
2013-06-20 |
Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations
|
Hsueh, YS;Lin, CL;Chiang, NJ;Yen, CC;Li, CF;Shan, YS;Ko, CH;Shih, NY;Wang, LM;Chen, TS;Chen, LT |
| 國家衛生研究院 |
2013-05 |
KRAS mutation status-stratified randomized phase II trial of GEMOX with and without cetuximab in advanced biliary tract cancer (ABTC): The TCOG T1210 trial
|
Chen, LT;Chen, JS;Chao, Y;Tsai, CS;Shan, YS;Hsu, C;Huang, SF;Tsou, HH;Lee, KD;Chiu, CF;Rau, KM;Ho, CL;Yu, MS;Taiwan Cooperative Oncology Group |
顯示項目 121-130 / 133 (共14頁)
<< < 5 6 7 8 9 10 11 12 13 14 > >>
每頁顯示[10|25|50]項目
|
